Stereotaxis and CardioFocus partner to develop robotic PFA technology

Stereotaxis (STXS) has announced a collaboration with CardioFocus to develop and commercialize robotic Pulsed Field Ablation (PFA) technology for treating cardiac arrhythmias, integrating Stereotaxis' magnetic navigation systems with CardioFocus' CE-marked Centauri PFA System. This partnership, which has completed preclinical testing and anticipates transitioning to human use soon, comes as Stereotaxis reported Q2 2025 revenue of $8.8 million and EPS of -$0.05, both exceeding analyst expectations. Despite the positive financial results and ongoing technological advancements, Stereotaxis' stock experienced an after-hours decline, indicating a nuanced market response.

Analysis

Stereotaxis (STXS) has entered a strategic collaboration with CardioFocus to develop and commercialize robotic Pulsed Field Ablation (PFA) technology for cardiac arrhythmias. This partnership integrates Stereotaxis' established robotic magnetic navigation systems with CardioFocus' CE-marked Centauri PFA System, which has already treated over 9,000 European patients. Extensive preclinical testing has demonstrated the integrated solution's ability to safely deliver deep, durable lesions, with human use and regulatory processes anticipated in the coming months.

The company reported strong Q2 2025 financial results, with revenue of $8.8 million surpassing analyst expectations of $7.75 million, and an EPS of -$0.05 outperforming the anticipated -$0.07. Concurrently, Stereotaxis achieved a significant technological milestone with Erasmus University Medical Center becoming the first in the Netherlands to utilize its Genesis Robotic Magnetic Navigation System. These developments underscore both financial outperformance and continued innovation in the medical technology space.

Despite these positive operational and financial announcements, Stereotaxis' stock experienced an after-hours decline, indicating a complex market response. This reaction occurs even as the company has seen an 85% stock gain over the past six months and InvestingPro analysis suggests it is currently trading near its fair value. The market's nuanced reaction warrants close monitoring of future developments and commercialization progress.

Key Decisions for Investors

• Monitor the progress of the robotic PFA collaboration, particularly regulatory approvals and the transition to human use, as this represents a significant growth vector for Stereotaxis.
• Despite the Q2 2025 financial beat, the after-hours stock decline suggests a cautious market sentiment, indicating potential profit-taking or concerns about valuation given the recent 85% gain.
• Evaluate the long-term implications of the PFA technology's adoption and Stereotaxis' ability to capitalize on this innovation, especially considering its current valuation near fair value.